Oncology
Primary Peritoneal Cancer
1
Pipeline Programs↗
14
Active Trials↗
14
Companies Involved↗
Primary Peritoneal Cancer is an early-stage landscape with 1 program across 14 companies. The most active players are K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc., Gynecologic Oncology Group, Eli Lilly.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
129
clinical trials
Completed79 · 61%
Terminated19 · 15%
Withdrawn10 · 8%
Active, not recruiting7 · 5%
Recruiting7 · 5%
Unknown status6 · 5%
Other1 · 1%
Clinical Trials
Trial Activity
129 trials
Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Recruiting·—·Phase 2·NCT05538091·48 enrolled
A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (DENALI / ZN-c3-005 / GOG-3066)
Recruiting·KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.·Phase 2·NCT05128825·310 enrolled
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Active, not recruiting·—·Phase 2·NCT04781088·38 enrolled
Page 1 of 9
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)